COMPANY PROFILE / #1154
Character Biosciences
Jersey City, NJVenture Capital-Backed
OVERVIEW
Developer of precision medicine designed to transform drug development for progressive, polygenic diseases. The company integrates genomics, clinical data, and AI-driven modeling to develop targeted therapies for dry age-related macular degeneration and primary open-angle glaucoma, enabling clinicians, researchers, and patients to create effective treatments, improve prediction of disease course, and focus therapies on individual patient needs.
已融资136.95
最新估值203.00
员工数48
成立年份2018
公司概况
- Companies
- Character Biosciences
- Description
- Developer of precision medicine designed to transform drug development for progressive, polygenic diseases. The company integrates genomics, clinical data, and AI-driven modeling to develop targeted therapies for dry age-related macular degeneration and primary open-angle glaucoma, enabling clinicians, researchers, and patients to create effective treatments, improve prediction of disease course, and focus therapies on individual patient needs.
- Website
- www.characterbio.com
- HQ Location
- Jersey City, NJ
- Year Founded
- 2018
- Keywords
- disease treatment, drug development, healthcare data analytics, medicine development, medicine research, ophthalmology care, precision medicine platform
- Competitors
- ARIEL Precision Medicine
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 136.95
- First Financing Date
- —
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 02-Sep-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 113.00
- Last Financing Valuation
- 203.00
- Last Financing Status
- Completed
- Last Known Valuation
- 203.00
- Last Known Valuation Date
- 02-Sep-2025
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 336.44
- Valuation Estimate Growth Rate
- 65.74%
- Active Investors
- aMoon Fund, Bausch + Lomb, Cantos Ventures, Casdin Capital, Catalio Capital Management, Clover Health Investments, Duke Capital Partners, EGR Partners, Industry Ventures, Innovation Endeavors Management Company, Jefferson Life Sciences, KdT Ventures, Lifeforce Capital, Luma Group, Milad Alucozai, Neman Ventures, S32, Sanofi Ventures
- # Active Investors
- 18
- Acquirers
- —
团队与联系人
- Employees
- 48
- Employee Growth %
- 50.00%
- Employee History
- 2025: 48, 2024: 32, 2023: 30, 2022: 16, 2021: 9
- Primary Contact
- Kaila Smilen
- Primary Contact Title
- Senior Director of Business Development & Corporate Strategy
- Primary Contact Email
- kaila.smilen@characterbio.com
- Primary Contact Phone
- +1 (888) 295-7659
增长与经营
- Revenue
- 1.00
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 21%
- Success Probability Over Time – 3 Year
- 38%
- Success Probability Over Time – 5 Year
- 51%
记录来源：public.companies · 原始序号 #1154 · 所有字段均按数据库原值展示。